共 50 条
- [1] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II StudyCLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648Mao, LiliFang, MeiyuChen, YuWei, XiaotingCao, JunLin, JingZhang, PengChen, LingCao, XiaoChen, YujunGuo, JunSi, Lu
- [2] Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 578 - 578Ren, ZhenggangGuo, YabingBai, YuxianYing, JieerMeng, ZhiqiangChen, ZhendongGu, ShanzhiZhang, JingdongLiang, JunHou, XinfangLi, WeiXu, AibingHao, ChunyiZhang, JianXing, RuijunZhang, XinyuZhang, DanChan, Stephen Lam
- [3] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Mao, LiliFang, MeiyuChen, YuBai, XueCao, JunLin, JingZhang, PengChen, LingXu, JiahuiGuo, JunSi, Lu
- [4] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Mao, LiliDai, JieBai, XueKong, YanSheng, XinanChi, ZhihongCui, ChuanliangLian, BinTang, BixiaYan, XieqiaoWang, XuanLi, SimingZhou, LiWei, XiaotingLi, JuanLi, CailiDuan, RongXu, HuayanGuo, JunSi, Lu
- [5] A phase 1, first-in-human, open-label, dose escalation study of MGD013, a bispecific DART® protein binding PD-1 and LAG-3 in patients with unresectable or metastatic neoplasmsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Shankar, SadhnaPatel, ManishBlumenschein, GeorgeHamilton, ErikaLuke, JasonMohs, Ross La-MotteShah, KalpanaAdali-Piston, LisaJohnson, SydBonivini, EzioMoore, PaulWigginton, JonVasselli, Jim
- [6] Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre studyANNALS OF ONCOLOGY, 2017, 28 (03) : 634 - 641McArthur, G. A.Maio, M.Arance, A.Nathan, P.Blank, C.Avril, M. -F.Garbe, C.Hauschild, A.Schadendorf, D.Hamid, O.Fluck, M.Thebeau, M.Schachter, J.Kefford, R.Chamberlain, M.Makrutzki, M.Robson, S.Gonzalez, R.Margolin, K.
- [7] Pd1 antibody sintilimab for dMMR/MSI-H locally advanced rectal cancer: An open-label, phase 2, single-arm study (cohort A).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Chen, GongWang, FengXiao, WeiweiJin, YingZhang, Rong-XinCai, PeiqiangLiu, MinHe, LongJunXi, ShaoYanChen, XiaobingZhang, HuizhongPan, Zhi-ZhongXu, Rui-hua
- [8] Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trialANNALS OF ONCOLOGY, 2024, 35 : S633 - S634Jiang, Y-F.Bei, W-X.Wang, L.Xu, C.Lu, N.Liang, H.Ke, L-R.Ye, Y-F.Fang, T.He, S.Dong, S-H.Liu, Q.Zhang, C.Xia, W.Zhao, C.Xie, C.Liu, G.Xiang, Y-Q.
- [9] A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Luke, Jason J.Patel, Manish R.Hamilton, Erika PaigeChmielowski, BartoszUlahannan, Susanna VarkeyKindler, Hedy L.Bahadur, Shakeela WazeenClingan, Philip R.Mallesara, GirishWeickhardt, Andrew JamesCurrence, ScottXu, LinzhiKaul, SanjeevChen, FrancineMoore, Paul A.Bonvini, EzioSumrow, BradBlumenschein, George
- [10] Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5340 - 5351Zager, Jonathan S.Orloff, MarlanaFerrucci, Pier FrancescoChoi, JunsungEschelman, David J.Glazer, Evan S.Ejaz, AslamHoward, J. HarrisonRichtig, ErikaOchsenreither, SebastianReddy, Sunil A.Lowe, Michael C.Beasley, Georgia M.Gesierich, AnjaBender, ArminGschnell, MartinDummer, ReinhardRivoire, MichelArance, AnaFenwick, Stephen WilliamSacco, Joseph J.Haferkamp, SebastianWeishaupt, CarstenJohn, JohnnyWheater, MatthewOttensmeier, Christian H.